Market closed
Assertio/$ASRT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Assertio
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Ticker
$ASRT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
53
Website
Assertio Metrics
BasicAdvanced
$80M
Market cap
-
P/E ratio
-$0.72
EPS
0.76
Beta
-
Dividend rate
Price and volume
Market cap
$80M
Beta
0.76
52-week high
$1.80
52-week low
$0.73
Average daily volume
1.1M
Financial strength
Current ratio
2.011
Quick ratio
1.482
Long term debt to equity
30.664
Total debt to equity
31.051
Interest coverage (TTM)
-5.93%
Management effectiveness
Return on assets (TTM)
-3.42%
Return on equity (TTM)
-42.36%
Valuation
Price to revenue (TTM)
0.638
Price to book
0.61
Price to tangible book (TTM)
2.09
Price to free cash flow (TTM)
3.945
Growth
Revenue change (TTM)
-25.77%
Earnings per share change (TTM)
-76.91%
3-year revenue growth (CAGR)
4.67%
3-year earnings per share growth (CAGR)
-1.98%
What the Analysts think about Assertio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Assertio stock.
Assertio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Assertio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Assertio News
AllArticlesVideos
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
GlobeNewsWire·4 days ago
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
GlobeNewsWire·1 week ago
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Assertio stock?
Assertio (ASRT) has a market cap of $80M as of December 21, 2024.
What is the P/E ratio for Assertio stock?
The price to earnings (P/E) ratio for Assertio (ASRT) stock is 0 as of December 21, 2024.
Does Assertio stock pay dividends?
No, Assertio (ASRT) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Assertio dividend payment date?
Assertio (ASRT) stock does not pay dividends to its shareholders.
What is the beta indicator for Assertio?
Assertio (ASRT) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.